prompting transition to swab enrichment of lavage specimens.
12 CVL provides an advantage over ECS in that increased surface area is sampled. 14 However, this increase in surface area prohibits identification of the location of HIV within the genital tract. In contrast, ECS allows for targeted sampling of the endocervical compartment but can also lead to blood contamination through abrasion and disruption of the mucosal barrier, which interferes with HIV VL quantification. 15 The MC has been proposed as an alternative genital sampling method, 16 based on its safety and acceptability for use during menses, [17] [18] [19] and the possibility for self-insertion, 16 which many women prefer. 20 The MC, like CVL, collects fluid from a larger surface area and larger sample volumes than ECS. 16 The MC has been used for in vitro assessments of HIV infection susceptibility and reproductive immunogenicity, 21, 22 but few studies have compared its performance to other collection methods.
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The optimal sampling method to measure genital HIV VL in women has not been determined. This study compares MC, ECS, and swab- were performed as a safety measure to reduce risk of possible pelvic inflammatory disease at the time of IUD insertion. Tests for these RTIs were repeated at the month 3 and 6 visits. At each visit, whole blood was collected from each woman and processed for HIV plasma VL.
| MATERIALS AND METHODS

This study was nested within a double-blinded (participants and
For each eligible woman providing consent, three different genital tract samples (MC, ECS, and eCVL) were collected for HIV RNA detection at enrollment and month 3 and 6 visits. Visits were scheduled to avoid menstrual bleeding, and women were instructed not to insert any products vaginally or to have vaginal intercourse 48 hours prior to the visit. Samples were obtained prior to IUD insertion at enrollment and, among women electing to continue the IUD, the IUD was in place during sampling at the 3-and 6-month visits. At each visit, women completed a sociodemographic, reproductive and sexual history questionnaire, as well as questions about their experiences with MC specimen collection.
| Genital specimen collection
For the MC sample, women either self-inserted (enrollment) or had a clinician insert (months 3, month and 6) an individually wrapped, single use Instead Softcup ™ (Evofem Inc., San Diego, CA, USA). Self-insertion was only feasible at enrollment, based on the order of specimen collection. The MC was inserted to cover the cervix and was to remain eCVL/MC/ECS). Specimen collection for NG, CT, TV, and BV tests always occurred after the eCVL.
| Genital sample processing
The 50-mL centrifuge tube containing the MC sample was weighed and the volume of secreted fluid calculated and recorded by subtracting the average weight of ten 50-mL tubes containing an unused MC.
Using a sterile wooden disposable spatula, the MC membrane was inverted to allow the content to collect at the bottom of the tube.
The tube was closed and centrifuged at 850 g for 10 minutes. After centrifugation, any residual secretion on the MC was removed by pipette, and the MC removed and discarded. The tube content was resuspended in PBS. Using the determined weight of secretions and assuming 1 g=1 mL genital secretion, a 10-fold dilution was made, which was aliquoted and stored at −70°C. For specimens weighing less than 0.08 g (n=6), an additional volume of PBS was added prior to aliquoting to ensure sufficient volume (0.6 mL) for the HIV assay. The ECS sample was resuspended by mixing the tube (ECS with 1.5 mL PBS) on a vortex mixer for 1 minute. All fluid was removed from the swab by gently scraping the swab head against the inside of the tube before discarding it. ECS samples were aliquoted and stored at −70°C.
The eCVL specimens were centrifuged at 850 g for 10 minutes with the swabs intact. HIV RNA contamination from a partner. As only one plate was available for this testing, eCVL samples were used due to larger number of available aliquots with this sampling method. For PSA testing, one aliquot from each enrollment eCVL specimen and from 13 specimens at month 3 and 14 specimens at month 6 was selected. At months 3 and 6, samples were selected based on genital tract HIV RNA levels, with equal inclusion of high (>50 000 copies/mL), medium (10 000-50 000 copies/ mL), and low (<10 000 copies/mL) VL measures to improve representation. All PSA samples were run on the same plate, and a standard curve constructed by plotting the mean absorbance for each standard run in duplicate. The concentration of PSA in each sample was determined by reading the absorbance from the standard curve generated. A PSA concentration >4 ng/mL was considered positive for semen contamination.
| HIV VL test
Each participant's plasma and genital tract MC, ECS, and eCVL specimens at each visit were tested for HIV RNA concentration using the Abbott M2000SP/RT viral load assay (Abbott Diagnostics, Illinois, USA) with a lower limit of detection of 40 copies/mL. This method has been validated at the National Health Laboratory Services Division of Medical Virology in South Africa for detection of HIV-1 subtype C in plasma. 25 Per laboratory protocol, specimen quantity of 0.6 mL was required for testing, with an additional 0.4 mL available for repeat assays.
| Statistical analysis
The primary outcome was genital HIV VL compared between paired MC, ECS, and eCVL specimens for each woman at each visit. HIV VL was dichotomized as non-detectable/non-quantifiable vs quantifiable with a continuous number recorded in copies/mL. For calculations of medians, non-quantifiable specimens were assigned a value of 40 copies/mL (the assay's lower detection limit), and specimens with non-detectable values were assigned a value of 20 copies/mL. For the MC, we also estimated Spearman's correlation between genital HIV VL and insertion time and specimen weight, respectively. We calculated 95% confidence intervals for Spearman's correlations using a
Fisher's Z transformation. To avoid the possibility of contamination by blood and/or semen, we ran sensitivity analyses restricting comparisons to specimens that did not test positive (3-4+) for hemoglobin, and women whose eCVL specimens did not test positive for PSA. We also ran a sensitivity analysis in which we gave any insufficient specimens a value of non-detectable to assess the impact of differential insufficient specimens by collection method on findings.
| RESULTS
Fifty-one women enrolled in this study, from whom a total of 148 specimens per collection method were analyzed for HIV V. three women missed their month 3, and two women their month 6 visits.
At enrollment, participants had a median age of 30 years (interquartile range, IQR, 26, 33), with a median time since HIV diagnosis of 44 months (IQR 13, 69). Most had experienced at least one pregnancy (94%) and were with a steady sexual partner (84%) at enrollment, as well as month 3 (81%) and month 6 (84%). At screening, 16% (n=8) tested positive for BV, 8% (n=4) for TV, 6% (n=3) for CT and 6% (n=3) for NG; all were treated prior to enrollment. The median CD4 count at screening was 571 cells/mm , and the median plasma VL at enrollment was 3.78 log 10 copies/mL, ranging from non-detectable (n=2) to 5.34 log 10 copies/mL. All women reported not using ART within the last 6 months at enrollment.
| Specimen quality: insufficient specimens, presence of hemoglobin, erythrocytes, and PSA
Across all visits, volumes recovered from MC specimens (13%) were more likely to be insufficient for HIV RNA VL testing, compared with ECS (2%, P=0.006) and eCVL (0%, P<0.001). Insufficient MC specimens were collected at each visit: n=4 at enrollment; n=2 at month 3; and n=6 at month 6. For potential blood contamination, in paired comparisons at enrollment, eCVL specimens (collected third) were significantly more likely to test positive for hemoglobin in the 3-4+ range (n=25, 49%) than the ECS (collected second, n=11, 21%, P=0.001) or the MC (collected first, n=8, 16%, P<0.001). There were no statistically significant differences in hemoglobin levels at the 3-and 6-month visits (ranging from 39%-50% of specimens positive in the 3-4+ range). In contrast to hemoglobin measurement, the presence of whole erythrocytes was very low, with only two MC (1%), three ECS (2%), and one eCVL (1%) specimen with high (3-4+) levels of erythrocytes across all visits (P>0.17 for each of the three paired comparisons). Seven (14%) enrollment eCVL specimens tested positive for PSA, suggesting recent unprotected sexual contact (≤48 hours); four of 13 were PSA-positive at month 3, and four of 14 at month 6.
| MC insertion time, weight, and acceptability
The median MC insertion time across all visits was 81 minutes (IQR 65, 103). As the MC insertion was the first specimen collected at enrollment, the median insertion time was longer than at months 3 
| HIV RNA VL by genital specimen collection method
Of all the methods compared, MC specimens had the highest proportion of quantifiable HIV RNA at enrollment and month 3 ( Figure 1 ). At enrollment, 60% of MC specimens had quantifiable HIV RNA compared to 38% of ECS (P=0.004) and 41% of eCVL specimens (P=0.004); in sensitivity analysis with insufficient specimens (n=4) coded as nondetectable, this became non-significant at P=0.065. This trend continued at the 3-month visit, with no significant differences in proportion quantifiable at month 6 (Table 1) . When restricted to paired specimens with quantifiable RNA, the median VL was significantly higher for MC specimens compared to both ECS and eCVL specimens, as 
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Among those with quantifiable HIV VL, median log 10 copies/mL of HIV RNA (IQR) Medians are presented for all of that type of specimen with quantifiable VL; P-values are computed for those in which both types of specimens had quantifiable VL.
seen in Table 1 . For all specimens, MC specimens had the highest median HIV VL compared to the other methods at each visit, regardless of collection order (Figure 2 ). In pooled analyses across visits, median VL was significantly higher for MC specimens (2.62 log 10 copies/mL) compared to ECS (1.30 log 10 copies/mL, P<0.001) or eCVL specimens (1.60 log 10 copies/mL, P<0.001). The median VL was also significantly higher in eCVL specimens compared to ECS specimens (P<0.001).
These comparisons remained statistically significant (P<0.001) when restricted to specimens that did not show signs of hemoglobin contamination and tested negative for the presence of male semen by PSA (data not shown). However, in sensitivity analysis in which insufficient specimens were coded as non-detectable, the eCVL now had a statistically significantly higher median VL than MC specimens (1.45 log 10 copies/mL, P < 0.001); both the eCVL and MC still had statistically significant higher median VL than the ECS.
| Correlation between HIV RNA concentrations in matching genital sample sets and plasma
We examined correlations between HIV RNA concentrations in (Table 1) .
| DISCUSSION
In this study, among pairs of sufficient specimens, MC specimens yielded higher median levels of HIV RNA than eCVL or ECS specimens, and eCVL specimens generally had higher levels than ECS. Both MC and eCVL methods sample a larger surface area of the lower reproductive tract than ECS, which may explain why these specimens yielded higher HIV VL than ECS. Another study comparing CVL (without swab enrichment) to MC for HIV-1 antibody (IgG) similarly found that MCs resulted in a higher proportion of specimens with detectable HIV-1 (99% of specimens vs 80%, P=0.029). 11 These findings may be due to greater time in the genital tract for collection or by the increased MC surface area and adherence of viscous secretions to the MC that do not easily dissolve in lavage fluid for eCVL. Alternately, the higher dilution volumes used for ECS and eCVL may have reduced the chances of HIV RNA detection by these methods simply due to the MC specimen being more concentrated. The similar rates of HIV RNA detection between MC and eCVL at visit 3, where eCVL was performed first, suggest dilution is less of an issue than actual quantity of genital tract secretions recovered.
Conversely, there were higher levels of insufficient specimens in the MC compared to ECS and eCVL across all visits. Correct placement of the MC may be harder to achieve than collection of cells from targeted sites using the eCVL and ECS. The issue of insufficient specimen may be greater for HIV RNA testing as a relatively large specimen is required, as compared to chemokine or RTI assays. The lower IQR of 0.15 g meant that 25% of samples had secretion weights below this value. Extra PBS was added to make up this volume to 0.6 mL, the minimum sample volume required for HIV RNA testing. Further, for some samples, repeated HIV RNA testing was required and the volume available was insufficient for this, resulting in insufficient sample status. For the ECS, the swab absorbs a considerable amount of the PBS.
The recovered volume was typically around 1.2 mL, of which 1 mL was sent for HIV RNA testing and volume for samples requiring repeat testing would have been insufficient.
Further, we eliminated more MC samples due to insufficient volume than eCVL or ECS, where a set dilution amount was used regardless of recovered genital tract fluid quantity. This exclusion of insufficient MC samples may have falsely elevated the proportion of MC samples with detectable HIV RNA. To counter this, in the sensitivity analysis in which we assumed all insufficient specimens were nondetectable, the eCVL had a higher median VL than the MC. However, this sensitivity analysis is a very conservative estimate; given that 54% of sufficient MC specimens had detectable RNA, it is unlikely that all 12 insufficient MC specimens would have been non-detectable had there been sufficient sample. Further research is needed on MC insertion and removal techniques to reduce the likelihood of insufficient specimen collection for HIV VL testing.
There were higher levels of hemoglobin in the eCVL compared to MC or ECS at the enrollment visit. This finding may be a result of the eCVL specimen being the last specimen to be collected at the enrollment visit. A study comparing eCVL and CVL found that eCVL at enrollment, and there were few incident infections detected in this group. Two women had undetectable plasma viral load at all visits and all participants, including these two women, had documented positive HIV antibody testing at screening. We note that other studies have attributed this finding to undisclosed ART use. 33 We do not believe that HIV RNA detection was impacted by the dilution factor used, identical to that of other studies and considered standard practice.
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Given the large number of factors that impact genital tract HIV RNA shedding, those detected in this study are within the range reported in the literature.
The MC appeared acceptable to most women, as only 6% reported difficulties with insertion, and, for each of these women, only at a single visit. Further, comfort level with the MC increased over time with women's use experience. Another study in South Africa similarly found that user comfort with the MC for menstrual management was high in this setting and increased over time. 19 All of the women in our study were willing to self-insert the MC at enrollment. In another study in South Africa, all 20 participants preferred for a provider to insert the MC, but only one-quarter were not willing to try self-insertion. MC sampling may also be completed by the patient herself, without provider time and associated cost. 
